Roth Capital Hikes Verona Pharma’s (VRNA) Price Target to $116 On COPD Market Prospects

Verona Pharma plc (NASDAQ:VRNA) is one of the 10 biotech stocks screaming a buy. On June 17, Roth Capital increased its price target to $116 from $92 while reiterating a Buy rating. The adjustment follows remarks by Dr Frank Sciurba, who discussed unmet chronic obstructive pulmonary disease needs.

A close up of a researcher in a laboratory, examining a new biopharmaceutical drug used to treat resistant bacterial infections.

The doctor shared positive insights on the company’s product Ohtuvayre, highlighting its complementary role in newly approved biologics. According to Roth Capital, the enhanced understanding of Verona Pharma’s Ohtuvayre’s distinctive efficacy and risk profile is already sparking greater interest among investors.

Consequently, the research firm raised its price target in response to the increased attention and appreciation of Verona Pharma’s offering. The research firm remains bullish about the company’s growth potential.

Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases. It focuses on developing treatments for chronic obstructive pulmonary disease (COPD). They are known for their product, ensifentrine, an investigational, inhaled, small molecule that acts as a dual inhibitor of phosphodiesterase 3 and 4 (PDE3 and PDE4), combining bronchodilator and anti-inflammatory properties.

While we acknowledge the potential of VRNA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On.

Disclosure: None.